Rheumatoid arthritis trials in Germany

In Germany 45 Also abroad 351

45 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
Where
Erlangen, Heidelberg
Age
18 years and over
People
56 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to join2024-519114-31-00 · EU 2024-519114-31-00
Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 1/2Taking people
Reduction of plasma cells as an approach to reset autoimmunity in rheumatoid arthritis
Where
Berlin, Erlangen
Age
18 years and over
People
23
Run by
Charite Universitaetsmedizin Berlin KöR
See details and how to join2024-511536-27-00 · EU 2024-511536-27-00
Phase 1Taking people
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Where
Bonn, Jena, Mainz, Muenster, Munich
Age
18 years to 65 years
People
48 worldwide
Run by
AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00
Phase 1/2Taking people
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Where
Berlin, Cologne, Herne, Munich, Sendenhorst
Age
18 years to 65 years
People
84 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07412704 · EU 2025-520666-22-00
Phase 1Taking people
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
Where
Berlin
Age
18 years to 70 years
People
36 worldwide
Run by
Jade Biosciences, Inc.
See details and how to joinNCT07533955
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
Where
Erlangen, Heidelberg
Age
18 years and over
People
37 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06994143
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Cologne, Erlangen, Magdeburg
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 1/2Taking people
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Where
Düsseldorf, Erlangen
Age
18 years and over
People
16 worldwide
Run by
Quell Therapeutics Limited
See details and how to joinNCT07473154
Phase 2Taking people
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Where
Dresden, Herne
Age
18 years and over
People
160 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07137598
Phase 2Taking people
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Where
Dresden, Herne
Age
18 years and over
People
120 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07620392 · EU 2025-523579-47-00
Phase 1/2Taking people
Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Where
Duesseldorf, Erlangen, Magdeburg
Age
18 years and over
People
8 worldwide
Run by
Quell Therapeutics Limited
See details and how to join2025-523971-46-00 · EU 2025-523971-46-00
No phaseTaking people
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Where
Altenburg, Amberg, Augsburg, Bad Endenbach, Bad Pyrmont, Bamberg, Berlin, Bielefeld, Braunschweig, Chemnitz, Coburg, Daun, Dresden, Düren, Ehringshausen, Elsterwerda, Erfurt, Erlangen, Euskirchen, Frankfurt am Main, Freiberg, Freiburg im Breisgau, Gifhorn, Greifswald, Halle, Hamburg, Hanover, Heidelberg, Herne, Hohen Neuendorf, Homburg, Hoppegarten, Kaiserslautern, Kassel, Kaufering, Leipzig, Ludwigslust, Magdeburg, Marktredwitz, Meerbusch, Monheim am Rhein, Munich, Naumburg, Neubrandenburg, Neunkirchen, Osnabrück, Pfarrkirchen, Planegg, Plauen, Potsdam, Püttlingen, Ratingen, Rendsburg, Schwerin, Templin, Tübingen, Ulm, Waren, Weimar, Weyhe, Wittlich, Wuppertal, Zweibrücken, Zwickau
Age
18 years and over
People
678
Run by
AbbVie
See details and how to joinNCT06712628
Phase 1Not yet taking people in Germany
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Berlin, Erlangen, Magdeburg, Würzburg
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 2Taking people
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Where
Bad Doberan, Berlin, Hamburg, Sendenhorst
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07276581
Phase 2Taking people
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Where
Bonn, Cologne, Frankfurt Am Main, Hamburg, Jena, Wetzlar
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT06972446 · EU 2025-520721-21-00
Phase 2Taking people
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
Where
Berlin, Hamburg, Sendenhorst
Age
18 years and over
People
97 worldwide
Run by
AstraZeneca AB
See details and how to join2025-522076-85-00 · EU 2025-522076-85-00
Phase 1Taking people
Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis
Where
Berlin
Age
18 years and over
People
24 worldwide
Run by
Jade Biosciences Inc.
See details and how to join2025-524746-96-00 · EU 2025-524746-96-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Cologne, Düsseldorf, Leipzig, München
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
No phaseNot yet taking people in Germany
DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
Where
Berlin, Bochum
Age
18 years to 80 years
People
320 worldwide
Run by
Centre Hospitalier Universitaire Vaudois
See details and how to joinNCT07857993
No phaseTaking people
Exactech Shoulder Post Market Clinical Follow-up Study
Where
Erlangen, Münster
Age
21 years and over
People
20,000 worldwide
Run by
Exactech
See details and how to joinNCT05603728
No phaseNot yet taking people in Germany
Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
Where
Berlin, Bochum
Age
18 years and over
People
142 worldwide
Run by
Centre Hospitalier Universitaire Vaudois
See details and how to joinNCT07825233
Phase 2Taking people
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors
Where
Dresden, Hamburg, Herne, Ratingen
Age
18 years and over
People
89 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2025-521034-28-00 · EU 2025-521034-28-00
Phase 1Taking people
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
Where
Berlin
Age
18 years and over
People
20
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2026-526282-25-00 · EU 2026-526282-25-00
Phase 1Taking people
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
Where
Heidelberg
Age
18 years and over
People
10
Run by
Universitaetsklinikum Heidelberg AöR
See details and how to join2024-519592-26-00 · EU 2024-519592-26-00